Literature DB >> 16234066

Natural killer cells in hepatitis C virus infection: from innate immunity to adaptive immunity.

Tetsuo Takehara1, Norio Hayashi.   

Abstract

Natural killer (NK) cells are specialized lymphocytes that provide a first line of defense through their ability to kill pathogen-infected cells and transformed cells. The function of NK cells is regulated by a fine balance of inhibitory and activating signals, which are mediated by a diverse array of cell-surface receptors. We recently found that expression of the inhibitory receptor CD94/NKG2A is up-regulated on NK cells in patients with chronic hepatitis C. HLA-E, a ligand for NKG2A, was expressed in all human hepatoma cell lines tested as well as in nontransformed hepatocytes, but not in K562 cells, a classic NK-sensitive target. NK cells isolated from patients with chronic hepatitis C (HCV-NK) were less capable of killing hepatoma cells and of producing interferon-gamma in response to hepatoma cells than those from healthy donors, whereas there was no significant difference in NK responsiveness toward K562 cells. Of note is the finding that maturation and activation of monocyte-derived dendritic cells were negatively modulated in the presence of HCV-NK and hepatoma cells, which were restored by the addition of anti-NKG2A antibody during the coculture of HCV-NK and hepatoma cells. Research revealed that dendritic cells recognize danger signals from microorganisms by monitoring pathogen-associated molecular patterns via Toll-like receptors. Our findings have shed light on NK receptors as an important interface that transmits danger signals from abnormal cells to immune systems. Aberrant expression of CD94/NKG2A should have negative impact on innate resistance and subsequent adaptive immunity toward HCV-infected or transformed cells in chronic hepatitis C.

Entities:  

Mesh:

Year:  2005        PMID: 16234066     DOI: 10.1016/s1542-3565(05)00702-0

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  13 in total

Review 1.  Acute hepatitis C virus infection: a chronic problem.

Authors:  Jason T Blackard; M Tarek Shata; Norah J Shire; Kenneth E Sherman
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

2.  Differential alteration of CD56(bright) and CD56 (dim) natural killer cells in frequency, phenotype, and cytokine response in chronic hepatitis C virus infection.

Authors:  Takuya Miyagi; Satoshi Shimizu; Tomohide Tatsumi; Kumiko Nishio; Naoki Hiramatsu; Tatsuya Kanto; Norio Hayashi; Tetsuo Takehara
Journal:  J Gastroenterol       Date:  2011-05-11       Impact factor: 7.527

Review 3.  Natural killer cell receptors and their ligands in liver diseases.

Authors:  Satoshi Yamagiwa; Hiroteru Kamimura; Takafumi Ichida
Journal:  Med Mol Morphol       Date:  2009-03-18       Impact factor: 2.309

Review 4.  A comparative review of HLA associations with hepatitis B and C viral infections across global populations.

Authors:  Rashmi Singh; Rashmi Kaul; Anil Kaul; Khalid Khan
Journal:  World J Gastroenterol       Date:  2007-03-28       Impact factor: 5.742

5.  KIR3DL1/S1 genotypes and KIR2DS4 allelic variants in the AB KIR genotypes are associated with Plasmodium-positive individuals in malaria infection.

Authors:  Michiko Taniguchi; Masato Kawabata
Journal:  Immunogenetics       Date:  2010-01-05       Impact factor: 2.846

6.  Phenotypic and functional changes of cytotoxic CD56pos natural T cells determine outcome of acute hepatitis C virus infection.

Authors:  Lucy Golden-Mason; Nicole Castelblanco; Cliona O'Farrelly; Hugo R Rosen
Journal:  J Virol       Date:  2007-06-06       Impact factor: 5.103

Review 7.  Natural killer cells: multifaceted players with key roles in hepatitis C immunity.

Authors:  Lucy Golden-Mason; Hugo R Rosen
Journal:  Immunol Rev       Date:  2013-09       Impact factor: 12.988

8.  Specific interaction of hepatitis C virus glycoproteins with mannan binding lectin inhibits virus entry.

Authors:  Kristelle S Brown; Michael J Keogh; Ania M Owsianka; Richard Adair; Arvind H Patel; James N Arnold; Jonathan K Ball; Robert B Sim; Alexander W Tarr; Timothy P Hickling
Journal:  Protein Cell       Date:  2010-07-29       Impact factor: 14.870

Review 9.  Antiviral therapy for chronic hepatitis C: past, present, and future.

Authors:  Norio Hayashi; Tetsuo Takehara
Journal:  J Gastroenterol       Date:  2006-01       Impact factor: 6.772

Review 10.  Involvement of activating NK cell receptors and their modulation in pathogen immunity.

Authors:  Francesco Marras; Federica Bozzano; Andrea De Maria
Journal:  J Biomed Biotechnol       Date:  2011-08-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.